It has been shown that the overexpression of EGFR in MCF-7 cells provides cancer cells with resistance to Fulv, and the resistant phenotype can be reversed upon cotreatment with a combination of Fulv and the EGFR inhibitors, erlotinib or gefitinib (44). The gene discussed is EGFR; the disease is cancer.